Spero Therapeutics
SPRO
59 hedge funds and large institutions have $47.5M invested in Spero Therapeutics in 2026 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 12 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
44% more capital inflows, than outflows
Capital inflows: $7.76M | Capital outflows: $5.4M
18% more funds holding
Funds holding: 50 → 59 (+9)
1.38% more ownership
Funds ownership: 35.66% → 37.04% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
43% less call options, than puts
Call options by funds: $260K | Put options by funds: $453K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Raymond James Financial
St Petersburg,
Florida
|
+$1.36M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.11M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$871K |
| 4 |
Goldman Sachs
New York
|
+$672K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$641K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$1.32M |
| 2 |
Anson Funds Management
Dallas,
Texas
|
-$987K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$985K |
| 4 |
Renaissance Technologies
New York
|
-$631K |
| 5 |
Squarepoint
New York
|
-$455K |
SPRO Hedge Fund Activity: Q2 2026 in Review
59 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q2 2026, worth a combined $47.5M — down 1.7% from $48.3M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new SPRO positions and 12 closed out — a net gain of 9 holders — while 16 added to existing stakes and 6 trimmed.
The largest buyer was Raymond James Financial, opening a new position worth an estimated $1.36M. The largest seller was Two Sigma Investments, cutting an estimated $1.32M.
- 59 institutional investors held Spero Therapeutics (SPRO) as of Q2 2026, up from 50 in Q1 2026.
- Funds reported $47.5M of Spero Therapeutics stock for Q2 2026, down 1.7% quarter-over-quarter.
- 21 funds opened new Spero Therapeutics positions in Q2 2026 and 12 closed out, a net change of +9 holders.
- The largest Spero Therapeutics buyer in Q2 2026 was Raymond James Financial, an estimated $1.36M added.
- The largest Spero Therapeutics seller in Q2 2026 was Two Sigma Investments, an estimated $1.32M sold.
Based on aggregated 13F filings for Q2 2026.